Melasma Monitoring Schedule: How Often to Check In and What to Track

What Melasma Is and Why Women Bear Most of the Burden

Melasma is a chronic, relapsing disorder of cutaneous hyperpigmentation driven by three intersecting forces: ultraviolet radiation, visible light, and hormones. Brown or gray-brown patches appear on the face, most often the cheeks, upper lip, forehead, and chin, though extrafacial melasma on the forearms and neck is documented in a smaller subset of patients.

Women account for approximately 90% of all melasma cases. That figure is not a coincidence. Estrogen and progesterone both stimulate melanocytes directly, upregulating tyrosinase, the rate-limiting enzyme in melanin synthesis. Pregnancy amplifies this effect sharply: studies report melasma in 50 to 70% of pregnant women in some cohorts and up to 90% in high-UV settings. The condition is called "chloasma" or the "mask of pregnancy" in older literature, but the biology is the same.

The clinical burden falls disproportionately on women with Fitzpatrick skin types III through VI, including women of Latina, South Asian, Middle Eastern, East Asian, and West African ancestry. These are also the populations least represented in treatment trials, which is a meaningful gap your clinician should account for when reading efficacy data.

Why This Is a Women's-Health Condition, Not Just a Dermatology Condition

Melasma does not exist in isolation from your reproductive history. Every hormonal transition in a woman's life, including starting or stopping oral contraceptives, becoming pregnant, postpartum estrogen withdrawal, the estrogen fluctuation of perimenopause, and initiation of hormone replacement therapy, can trigger, worsen, or briefly improve the condition. Monitoring melasma without tracking hormonal status misses half the picture.

How Melasma Is Diagnosed

Diagnosis is clinical in most cases. A trained clinician inspects the distribution, color, and borders of the patches under good lighting and confirms the finding with a Wood's lamp, a handheld device emitting 365 nm ultraviolet light.

Wood's Lamp Classification

The Wood's lamp separates melasma into four subtypes that predict treatment response:

| Subtype | Wood's Lamp Appearance | Depth | Treatment Response | |---|---|---|---| | Epidermal | Enhanced contrast (darker under lamp) | Superficial | Best | | Dermal | No enhancement | Deep | Poor | | Mixed | Partial enhancement | Both layers | Moderate | | Indeterminate | Unclear | Variable | Unpredictable |

Epidermal melasma responds best to topical depigmenting agents. Dermal melasma, where pigment sits in dermal macrophages rather than epidermal melanocytes, responds poorly to standard creams and may require procedural approaches. The Wood's lamp classification is not perfectly predictive, but it guides expectations and should be documented at baseline.

Objective Scoring: MASI and mMASI

The Melasma Area and Severity Index (MASI) scores pigmentation across four facial regions weighted by area. The modified MASI (mMASI), which removes the homogeneity subscale, has been validated as the more reproducible tool in a 2011 reliability study. Most trials now use mMASI as their primary endpoint.

A baseline mMASI score should be recorded at your first visit. Photograph standardization matters too: consistent lighting, distance, and camera angle are necessary to track change. Some clinics use cross-polarized photography to better visualize dermal pigment.

Ruling Out Other Causes

Before committing to a melasma treatment plan, your clinician should consider diagnoses that mimic it:

• Post-inflammatory hyperpigmentation (history of acne, eczema, or injury)
• Drug-induced pigmentation (minocycline, amiodarone, antimalarials)
• Lichen planus pigmentosus (often in darker skin types, more diffuse)
• Addison's disease (diffuse hyperpigmentation with systemic symptoms)
• Erythema dyschromicum perstans

A thyroid panel (TSH, free T4) is reasonable in women with new-onset melasma and no clear hormonal trigger, since autoimmune thyroid disease clusters with other pigmentary disorders and is far more common in women.

The Exact Monitoring Schedule by Phase

This is the section most melasma content skips or vagues over. Here is a specific schedule, anchored to treatment phase and life stage.

Phase 1: Baseline Visit (Week 0)

At the first visit your clinician should:

1. Document Wood's lamp subtype
2. Record baseline mMASI score and standardized photographs
3. Review full hormonal history: current contraception, cycle regularity, pregnancy plans, perimenopausal symptoms, any HRT
4. Assess Fitzpatrick skin type
5. Confirm sun protection behavior (SPF type, application frequency, hat use, shade-seeking)
6. Order TSH if no clear hormonal trigger and systemic symptoms are present
7. Confirm no contraindications to planned topical agents (pregnancy status is mandatory before prescribing hydroquinone or tretinoin)

Phase 2: Active Treatment Monitoring (Weeks 8 through 24)

Return visits every 8 to 12 weeks during active treatment. At each visit:

• Repeat mMASI and compare to baseline
• Assess for treatment side effects: irritation, contact dermatitis, paradoxical hyperpigmentation (especially relevant in darker skin types on strong concentrations)
• Confirm sunscreen adherence. UV exposure remains the most common reason treatment fails even when the topical agent is effective
• Review any intervening hormonal changes (new OCP, missed pills, pregnancy test if indicated)

A meaningful response is generally defined as a 50% or greater reduction in mMASI from baseline by week 24. The landmark Kligman formula trial (hydroquinone 4% plus tretinoin 0.05% plus fluocinolone acetonide 0.01%) demonstrated this level of response in 77% of participants at 24 weeks. If you are not tracking mMASI at each visit, you cannot assess whether you are in that 77% or not.

Phase 3: Maintenance and Remission Monitoring (Month 6 onward)

Once a target response is achieved, the monitoring interval extends to every 3 to 6 months. Maintenance visits should:

• Repeat mMASI (or at minimum, standardized photographs)
• Assess for relapse triggers: season change (UV index increase in spring), hormonal shifts, new skincare products
• Adjust maintenance regimen if needed. Azelaic acid 20% or topical niacinamide are common maintenance agents with more favorable tolerability profiles than hydroquinone for long-term use

Melasma has a high relapse rate. One 12-month follow-up study found that over 60% of women who achieved clearance on tri-combination therapy relapsed within one year without maintenance sunscreen and depigmenting agents. Monitoring does not stop at remission.

Unscheduled (Trigger-Based) Review

Any of the following should prompt an earlier review regardless of where you are in your scheduled interval:

• Starting or stopping an OCP or other hormonal contraceptive
• Confirmed pregnancy or postpartum period
• Beginning or discontinuing HRT
• Significant sun exposure event (vacation, outdoor work change)
• New or worsening patches despite adherence
• Skin irritation or suspected contact dermatitis from topical agents

Hormonal Triggers Across Every Life Stage

Reproductive Years: OCPs and Cycle-Linked Fluctuation

Combined oral contraceptive pills containing estrogen and progestin are a well-documented melasma trigger, with some estimates placing OCP-associated melasma at 10 to 25% of cases in women of reproductive age. If you develop new patches within 3 to 6 months of starting a combined OCP, the contraceptive is a likely contributor.

Options to discuss with your clinician include switching to a progestin-only pill, an IUD (hormonal or copper), or a non-hormonal method. Switching does not guarantee improvement. Dermal pigment deposited during months of hormonal exposure does not clear automatically once the stimulus is removed, but removing the ongoing trigger can slow new patch formation.

Trying to Conceive and Pregnancy

This is one of the most consequential monitoring moments. If you are actively trying to conceive, your treatment plan needs to be restructured before you stop contraception, not after a positive test.

Hydroquinone is FDA Pregnancy Category C based on animal data showing systemic absorption. Tretinoin is FDA Pregnancy Category X, contraindicated in pregnancy due to teratogenic risk from systemic retinoid exposure. Both should be discontinued before conception attempts.

Azelaic acid 20% cream is FDA Pregnancy Category B and is the most commonly recommended agent for use during pregnancy in women who require some treatment, though most clinicians prefer to defer active depigmenting treatment until after delivery and stopping breastfeeding.

Sun protection is the one intervention safe and recommended throughout pregnancy: a broad-spectrum mineral sunscreen (zinc oxide or titanium dioxide) with SPF 30 or higher, applied every 2 hours during UV exposure, is appropriate for all trimesters.

Postpartum and Lactation

Melasma acquired during pregnancy may begin to fade in the months after delivery as estrogen levels fall, but it does not always resolve fully. The timeline varies considerably. If patches persist beyond 3 months postpartum and you are breastfeeding, most topical treatments remain restricted.

Hydroquinone transfers into breast milk at low but unmeasured levels; most guidelines recommend avoiding it during lactation. Tretinoin is not recommended during breastfeeding. Azelaic acid has limited human lactation data but is generally considered lower risk given its topical, limited systemic absorption profile. The decision to treat during lactation requires an individual risk-benefit discussion with your clinician.

Monitoring during the postpartum period should occur at the 6-week postpartum visit, with a dedicated skin re-assessment to document whether melasma is improving, stable, or worsening, and to plan treatment re-initiation once breastfeeding concludes.

Perimenopause

Perimenopausal estrogen fluctuation, characterized by erratic cycling and intermittently high estradiol levels before the eventual decline, can trigger new melasma or worsen existing patches in your 40s even before your periods become irregular. This is a frequently underrecognized trigger.

If you have a personal history of melasma and are approaching perimenopause, your monitoring interval should remain at least every 6 months rather than extending further. Any addition of estrogen-containing HRT requires re-evaluation of melasma severity within 8 to 12 weeks of initiation.

Postmenopause and HRT

Women who start hormone replacement therapy post-menopause, particularly estrogen-progestin combinations, may see melasma recur or appear for the first time. A cross-sectional analysis confirmed that exogenous estrogen exposure is an independent predictor of melasma regardless of age. Transdermal rather than oral estrogen delivers lower peak estrogen levels and may be a consideration, though direct comparative data on melasma risk by HRT route is limited, which is a genuine evidence gap.

Treatment Overview and How It Connects to Monitoring

Monitoring is meaningful only when there is a treatment plan it can assess. Here is a concise treatment framework organized by evidence level.

First-Line: Topical Tri-Combination Therapy

The FDA-approved tri-combination cream (hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%, brand name Tri-Luma) remains the best-studied first-line agent. In the key 8-week RCT, 77% of participants achieved treatment success versus 46% for dual-agent controls. It is not intended for use beyond 8 weeks continuously due to corticosteroid-related risks from the fluocinolone component. Your monitoring schedule at week 8 is therefore a critical decision point: assess response, then transition to a maintenance regimen.

Second-Line Options

• Azelaic acid 20%: Inhibits abnormal melanocyte proliferation. Comparable to hydroquinone 4% monotherapy in a meta-analysis with a superior tolerability profile for sensitive or darker skin types. Pregnancy Category B.
• Tranexamic acid (oral or topical): A newer option with growing evidence. Oral tranexamic acid 250 mg twice daily reduced mMASI scores by 49% at 12 weeks in a 2020 RCT. Oral dosing is off-label in most countries for melasma; prescribers should review thromboembolic risk in individual patients, particularly in women with a history of thrombosis or who smoke.
• Niacinamide 4-5% (topical): Modest evidence, good tolerability, appropriate for long-term maintenance.
• Sunscreen as monotherapy: A 2013 randomized trial demonstrated that broad-spectrum SPF 50+ sunscreen alone improved mMASI scores more than untreated controls over 12 weeks, confirming that sun protection is not merely adjunctive.

Procedural Options (When Topicals Fail)

Chemical peels (glycolic acid, salicylic acid, or Jessner's solution), low-fluence Q-switched Nd:YAG laser, and non-ablative fractional laser are documented options for refractory melasma. These require careful patient selection by Fitzpatrick skin type since post-inflammatory hyperpigmentation risk is substantial in darker skin. Procedures should be followed with the same 8-to-12-week monitoring interval.

Who This Monitoring Schedule Is Right For, and Who Needs a Modified Approach

Most women with clinically confirmed melasma benefit from the schedule above. Several subgroups require adjustment.

You may need more frequent monitoring (every 4 to 6 weeks) if:

• You are in the first trimester of pregnancy with severe, rapidly expanding patches
• You are using tretinoin for the first time and have Fitzpatrick type IV or higher (higher irritation and paradoxical hyperpigmentation risk)
• You are using oral tranexamic acid and have cardiovascular risk factors
• You have a history of contact dermatitis or significantly sensitive skin

You may extend monitoring to every 6 months if:

• You have achieved a stable response on maintenance sunscreen alone
• You are postmenopausal, not on HRT, and have had no new patches in 12 months
• Your only treatment is topical niacinamide or azelaic acid with excellent adherence and no new hormonal triggers

Modified approach for darker skin types (Fitzpatrick V-VI): Avoid high-concentration hydroquinone (above 4%) without close monitoring. Tretinoin irritation causing post-inflammatory darkening can worsen melasma. Start low (tretinoin 0.025%), advance slowly, and assess at 6 rather than 8 weeks for early irritation signals. The evidence base for safe, effective treatment in Fitzpatrick V-VI skin is genuinely thinner than for lighter skin types, and your clinician should acknowledge this directly.

The Evidence Gap: What We Know and What We Do Not

Women of color carry the highest melasma burden globally, yet a 2021 systematic review found that fewer than 35% of melasma RCT participants had Fitzpatrick skin types V or VI. Most monitoring interval recommendations in clinical guidelines are extrapolated from trials in lighter skin types or from general dermatology practice rather than melasma-specific controlled data.

"The monitoring schedule for melasma should never be static," said Dr. Rachel Goldberg, MD, WomanRx editorial board reviewer. "Every hormonal event in a woman's life, from a new OCP prescription to a perimenopause diagnosis, is a reason to reassess her skin and her treatment plan. An 8-week check-in is a minimum, not a ceiling."

Tranexamic acid dosing, the optimal laser parameters for darker skin, and the best maintenance strategy for postpartum women who want to resume treatment quickly are all areas where high-quality randomized data in women specifically is still missing. When your clinician recommends a treatment in these areas, ask directly whether the evidence comes from a study population that looks like you.

A Practical Monitoring Checklist for Your Next Visit

Bring this to every melasma appointment:

• Current sunscreen name, SPF, and how often you apply it
• Any new hormonal medications started or stopped since your last visit
• Standardized selfies in the same lighting and position (a window-lit bathroom, same time of day)
• A note on any new skincare products introduced
• Your last mMASI score (ask your clinician to share this number with you)
• Pregnancy status or active conception plans

Your clinician should document mMASI at every visit. If they are not, ask for it. A number gives you and your provider a shared language for whether treatment is working.